210 related articles for article (PubMed ID: 28548891)
1. Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy.
Bamias G; Delladetsima I; Perdiki M; Siakavellas SI; Goukos D; Papatheodoridis GV; Daikos GL; Gogas H
Cancer Invest; 2017 Aug; 35(7):443-455. PubMed ID: 28548891
[TBL] [Abstract][Full Text] [Related]
2. Th17 cells induce colitis and promote Th1 cell responses through IL-17 induction of innate IL-12 and IL-23 production.
Feng T; Qin H; Wang L; Benveniste EN; Elson CO; Cong Y
J Immunol; 2011 Jun; 186(11):6313-8. PubMed ID: 21531892
[TBL] [Abstract][Full Text] [Related]
3. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.
Jain A; Lipson EJ; Sharfman WH; Brant SR; Lazarev MG
World J Gastroenterol; 2017 Mar; 23(11):2023-2028. PubMed ID: 28373768
[TBL] [Abstract][Full Text] [Related]
4. Management of immune-related adverse events and kinetics of response with ipilimumab.
Weber JS; Kähler KC; Hauschild A
J Clin Oncol; 2012 Jul; 30(21):2691-7. PubMed ID: 22614989
[TBL] [Abstract][Full Text] [Related]
5. Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis.
Verschuren EC; van den Eertwegh AJ; Wonders J; Slangen RM; van Delft F; van Bodegraven A; Neefjes-Borst A; de Boer NK
Clin Gastroenterol Hepatol; 2016 Jun; 14(6):836-842. PubMed ID: 26748223
[TBL] [Abstract][Full Text] [Related]
6. 1,25-dihydroxyvitamin D3 regulates the development of chronic colitis by modulating both T helper (Th)1 and Th17 activation.
Zhang H; Wu H; Liu L; Li H; Shih DQ; Zhang X
APMIS; 2015 Jun; 123(6):490-501. PubMed ID: 25907285
[TBL] [Abstract][Full Text] [Related]
7. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
Rismo R; Olsen T; Cui G; Christiansen I; Florholmen J; Goll R
Scand J Gastroenterol; 2012 May; 47(5):538-47. PubMed ID: 22486187
[TBL] [Abstract][Full Text] [Related]
8. Systematic review: colitis associated with anti-CTLA-4 therapy.
Gupta A; De Felice KM; Loftus EV; Khanna S
Aliment Pharmacol Ther; 2015 Aug; 42(4):406-17. PubMed ID: 26079306
[TBL] [Abstract][Full Text] [Related]
9. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.
Berman D; Parker SM; Siegel J; Chasalow SD; Weber J; Galbraith S; Targan SR; Wang HL
Cancer Immun; 2010 Nov; 10():11. PubMed ID: 21090563
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab-induced colitis in patients with metastatic melanoma.
De Felice KM; Gupta A; Rakshit S; Khanna S; Kottschade LA; Finnes HD; Papadakis KA; Loftus EV; Raffals LE; Markovic SN
Melanoma Res; 2015 Aug; 25(4):321-7. PubMed ID: 25933207
[TBL] [Abstract][Full Text] [Related]
11. Interferon-γ induces expression of MHC class II on intestinal epithelial cells and protects mice from colitis.
Thelemann C; Eren RO; Coutaz M; Brasseit J; Bouzourene H; Rosa M; Duval A; Lavanchy C; Mack V; Mueller C; Reith W; Acha-Orbea H
PLoS One; 2014; 9(1):e86844. PubMed ID: 24489792
[TBL] [Abstract][Full Text] [Related]
12. IL-17/IFN-γ interactions regulate intestinal inflammation in TNBS-induced acute colitis.
Jin Y; Lin Y; Lin L; Zheng C
J Interferon Cytokine Res; 2012 Nov; 32(11):548-56. PubMed ID: 23030668
[TBL] [Abstract][Full Text] [Related]
13. Faecalibacterium prausnitzii supernatant ameliorates dextran sulfate sodium induced colitis by regulating Th17 cell differentiation.
Huang XL; Zhang X; Fei XY; Chen ZG; Hao YP; Zhang S; Zhang MM; Yu YQ; Yu CG
World J Gastroenterol; 2016 Jun; 22(22):5201-10. PubMed ID: 27298563
[TBL] [Abstract][Full Text] [Related]
14. Bifidobacterium infantis attenuates colitis by regulating T cell subset responses.
Zuo L; Yuan KT; Yu L; Meng QH; Chung PC; Yang DH
World J Gastroenterol; 2014 Dec; 20(48):18316-29. PubMed ID: 25561798
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
16. Increased CD4
Ma YH; Zhang J; Chen X; Xie YF; Pang YH; Liu XJ
World J Gastroenterol; 2016 Nov; 22(42):9356-9367. PubMed ID: 27895423
[TBL] [Abstract][Full Text] [Related]
17. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion.
Liu Z; Jiu J; Liu S; Fa X; Li F; Du Y
J Autoimmun; 2007; 29(2-3):187-94. PubMed ID: 17804196
[TBL] [Abstract][Full Text] [Related]
18. A CD3-specific antibody reduces cytokine production and alters phosphoprotein profiles in intestinal tissues from patients with inflammatory bowel disease.
Vossenkämper A; Hundsrucker C; Page K; van Maurik A; Sanders TJ; Stagg AJ; Das L; MacDonald TT
Gastroenterology; 2014 Jul; 147(1):172-83. PubMed ID: 24704524
[TBL] [Abstract][Full Text] [Related]
19. Pathogenicity of In Vivo Generated Intestinal Th17 Lymphocytes is IFNγ Dependent.
Nizzoli G; Burrello C; Cribiù FM; Lovati G; Ercoli G; Botti F; Trombetta E; Porretti L; Todoerti K; Neri A; Giuffrè MR; Geginat J; Vecchi M; Rescigno M; Paroni M; Caprioli F; Facciotti F
J Crohns Colitis; 2018 Jul; 12(8):981-992. PubMed ID: 29697763
[TBL] [Abstract][Full Text] [Related]
20. Infliximab Therapy for Corticosteroid-Resistant Ipilimumab-Induced Colitis.
Beniwal-Patel P; Matkowskyj K; Caldera F
J Gastrointestin Liver Dis; 2015 Sep; 24(3):274. PubMed ID: 26405697
[No Abstract] [Full Text] [Related]
[Next] [New Search]
